Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

Cannasat Taps IntelGenx to Facilitate Development of Cannabinoid-Based Products for Mood Disorders

  • Cannasat Therapeutics and IntelGenx will together develop a cannabinoid-based product through a combination of Cannasat's and IntelGenx's drug delivery technologies. CAT 320 targets the endocannabinoid system to treat mood disorders, such as anxiety and depression.

    Cannasat will leverage IntelGenx' experience in developing oral, sublingual, and transdermal formulations. IntelGenx' will help address the challenges of achieving rapid onset, improving therapeutic efficacy, and minimizing the total dose required to treat disease conditions.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »